Five Prime Therapeutics (FPRX) Announces Data on B7-H4 Therapeutic Antibody at 2018 AACR Annual Meeting
Tweet Send to a Friend
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced that an oral presentation featuring FPA150, Five Prime’s first-in-class B7-H4 antibody, was given ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
